Hepatitis B vaccine recombinant - Crucell

Drug Profile

Hepatitis B vaccine recombinant - Crucell

Alternative Names: AgB; Biovac-B; Hepavax-Gene; Hepavax-Gene TF; Supervax

Latest Information Update: 15 May 2014

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Crucell; Dynavax Dusseldorf
  • Developer Crucell; Dynavax Dusseldorf; Laboratorio Pablo Cassara
  • Class Hepatitis B vaccines; Synthetic vaccines
  • Mechanism of Action Immunostimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Marketed Hepatitis B

Most Recent Events

  • 01 Nov 2013 Crucell completes a phase III trial in Hepatitis B prevention in China (NCT01349283)
  • 07 Jul 2011 Crucell initiates enrolment in a phase III trial in Hepatitis B pervention in China (NCT01349283)
  • 22 Feb 2011 Crucell has been acquired by Johnson & Johnson
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top